Delving into the Latest Updates on OncoMab GmbH with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
免疫系统疾病	1
肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

HSPA5 x Low-density lipoprotein	1

关联

3

项与 OncoMab GmbH 相关的药物

PAT-SM6

靶点

HSPA5 x Low-density lipoprotein

作用机制

HSPA5抑制剂 [+1]

在研机构

Patrys Ltd. [+1]

原研机构

OncoMab GmbH

在研适应症

多发性骨髓瘤 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

PAT-PM-1

靶点-

作用机制

IgM 激动剂

在研机构-

原研机构

OncoMab GmbH

在研适应症-

非在研适应症

胰腺癌

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

PAT-PM-2

靶点-

作用机制

IgM 激动剂

在研机构-

原研机构

OncoMab GmbH

在研适应症-

非在研适应症

肿瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 OncoMab GmbH 相关的临床结果

登录后查看更多信息

0 项与 OncoMab GmbH 相关的专利（医药）

登录后查看更多信息

2

项与 OncoMab GmbH 相关的文献（医药）

2005-01-22·Human Antibodies

PAM-1, a natural human IgM antibody as new tool for detection of breast and prostate precursors

Article

作者: Müller-Hermelink, Hans Konrad ; Eck, Matthias ; Ströbel, Philipp ; Vollmers, H. Peter ; Hensel, Frank ; Brändlein, Stephanie ; Wozniak, Ewa

Early detection and differential analysis of premalignant lesions are very important for both prognosis and therapy of cancer patients. A good source of diagnostic tools is the natural antibody pool of humans. Tumor-specific antibodies can be established by using hybridoma technology. The fully human germline-coded monoclonal IgM antibody PAM-1 was isolated from a patient with a stomach carcinoma. PAM-1 reacts with a post-transcriptionally modified isoform of membrane receptor CFR-1 which is overexpressed on almost all epithelial cancers of all types and origins. The expression of CFR-1/PAM-1 on precancerous stages of breast and prostate cancer was analyzed by immunohistochemistry and compared with normal breast and prostate tissue as well as adenocarcinomas of both. In addition FACS analysis was performed to detect receptor expression on benign and malign prostate cells. 73 different tissue samples of prostate and breast precancerous stages and prostate and breast carcinomas were analysed for CFR-1/PAM-1 expression immunohistochemically. The CFR-1/PAM-1 receptor was expressed on nearly all precancerous stages and carcinomas while normal breast and prostate tissue showed negative results. These results were confirmed by FACS analysis showing a CFR-1/PAM-1 expression only on prostate carcinoma cells but not on benign prostate hyperplasia cells. The unique expression of this new CFR-1/PAM-1 receptor makes the PAM-1 antibody an ideal diagnostic and even therapeutic tool for precancerous and cancerous epithelial lesions of the breast and the prostate.

2004-07-15·Journal of Clinical Oncology

Prognostic effect of CD55^SC-1 in gastric carcinoma (GC) and survival after treatment with the monoclonal antibody SC-1

作者: Vollmers, H. P. ; Hensel, F. ; Reindl, H. ; Coquoz, D. ; Rückle-Lanz, H. ; Wilhelm, M. ; Timmermann, W. ; Müller-Hermelink, H. K. ; Thiede, A. ; Illert, B.

100 项与 OncoMab GmbH 相关的药物交易

登录后查看更多信息

100 项与 OncoMab GmbH 相关的转化医学

登录后查看更多信息